Misplaced Pages

Cipemastat: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 18:14, 28 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Wikipedia_talk:WikiProj...← Previous edit Revision as of 13:11, 29 January 2013 edit undoJYBot (talk | contribs)Extended confirmed users42,944 editsm r2.7.1) (Robot: Adding fa:سیپماستاتNext edit →
Line 48: Line 48:


{{musculoskeletal-drug-stub}} {{musculoskeletal-drug-stub}}

]

Revision as of 13:11, 29 January 2013

Cipemastat
Names
IUPAC name (2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-butanamide
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1Key: GFUITADOEPNRML-SJORKVTESA-N
  • InChI=1/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1Key: GFUITADOEPNRML-SJORKVTEBV
SMILES
  • CC1(C)NC(=O)N(C((CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C1=O
Properties
Chemical formula C22H36N4O5
Molar mass 436.545 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Cipemastat (rINN, also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent. It is being developed by Roche.

References

  1. Hemmings F, Farhan M, Rowland J, Banken L, Jain R (2001). "Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis". Rheumatology (Oxford). 40 (5): 537–43. doi:10.1093/rheumatology/40.5.537. PMID 11371662.{{cite journal}}: CS1 maint: multiple names: authors list (link)


Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Cipemastat: Difference between revisions Add topic